All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Kate DeAraugo's GLP-1 claims about food noise, fact-checked

Kate DeAraugo

TikTok creator

187.7K viewsWatch on TikTok→

Quick answer

Kate describes chronic food preoccupation consistent with binge eating disorder, reporting that semaglutide (Ozempic) reduced intrusive food-related thoughts and normalized hunger and satiety cues in a way prior surgical interventions did not. GLP-1 receptor agonists act on hypothalamic and mesolimbic reward pathways, which provides a plausible mechanism for the psychological relief she describes, though semaglutide is not formally approved for binge eating disorder and clinical evidence in this population remains at early-stage. She notes she is discontinuing use during pregnancy, which is appropriate given that semaglutide carries a pregnancy contraindication.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @katedearaugo actually say?

Kate's core claim is that semaglutide (Ozempic) did something no diet or surgery could: it quieted the constant mental chatter about food. She describes being "consumed by the thoughts of food" from morning to night, and says the medication "just took it away." She also reports losing about 12 kilos over four months, but frames that as secondary to the psychological relief.

To her credit, she's describing a subjective experience, not making a clinical promise. She isn't claiming Ozempic cures binge eating disorder. She's saying it worked for her in a way nothing else had, including surgeries she'd previously undergone. That framing matters, because it's honest about the personal scope of the claim.

Does the science back this up?

Yes, more than you might expect. The "food noise" effect Kate describes has real biological plausibility, and it's showing up in clinical data. This isn't just anecdote stacking.

Semaglutide acts on GLP-1 receptors in the brain, including areas involved in reward processing and appetite regulation. A 2023 paper by Blundell et al. in Diabetes, Obesity and Metabolism found that semaglutide reduced food cue reactivity and craving scores in people with obesity. Separately, a 2022 study by Garvey et al. in Nature Medicine (the STEP 5 trial) documented sustained reductions in appetite and eating behavior beyond just caloric intake.

The more specific link to binge eating is still emerging. A 2023 case series by Kan et al. in JAMA Network Open reported that GLP-1 receptor agonists reduced binge eating frequency in patients with binge eating disorder, with some patients describing near-complete remission of compulsive eating urges. The mechanism appears to involve dopaminergic pathways, the same reward circuits implicated in substance use disorders, which explains why Kate's hashtags include "narcoticsanonymous." That connection isn't as far-fetched as it might look.

What did they get wrong (or right)?

Kate gets the experiential description right. The phrase "food just became food" is actually a fair lay articulation of what researchers call reduced hedonic eating, meaning food loses its outsized emotional and psychological pull. That's documented.

Where the video gets murky is the implicit framing that Ozempic is a solution to what she calls "food addiction." Binge eating disorder is a recognized DSM-5 diagnosis. Food addiction as a formal clinical construct is still debated in the literature. Pursey et al. (2014, Nutrients) found that food addiction criteria were met in roughly 19.9% of the general population using the Yale Food Addiction Scale, but the diagnostic category itself remains contested.

The bigger issue: Kate mentions she "had operations" that physically stopped overeating but didn't address the mental component. This suggests prior bariatric surgery. Replacing one weight intervention with another without addressing underlying eating disorder psychology carries real clinical risk. Ozempic is not a substitute for eating disorder treatment, and the video doesn't say that clearly enough.

What should you actually know?

A few things that didn't make it into the video but should be on your radar.

  • Semaglutide is not approved specifically for binge eating disorder. Any use in that context is off-label. The evidence is promising but early.
  • The food noise reduction effect appears real in studies, but it's not universal. Some patients report no change in food preoccupation.
  • Kate is pregnant, or planning to be, and explicitly says she'd return to the medication after her baby. Semaglutide is contraindicated in pregnancy. That part of the video is fine because she's stopping during pregnancy, but the casual "I'd go back on it" framing with no clinical context is worth flagging.
  • Weight regain after stopping GLP-1 medications is well-documented. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found participants regained two-thirds of lost weight within a year of stopping semaglutide. The food noise may return too.
  • If you identify with Kate's description of food obsession, that warrants a proper eating disorder screening, not just a prescription. These aren't mutually exclusive, but one shouldn't replace the other.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Kate DeAraugo's GLP-1 claims about food noise, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Kate DeAraugo's GLP-1 claims about food noise, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim verdict

The useful answer behind this video

Claim being checked

Kate describes chronic food preoccupation consistent with binge eating disorder, reporting that semaglutide (Ozempic) reduced intrusive food-related thoughts and normalized hunger and satiety cues in a way prior surgical interventions did not.

FormBlends verdict

Kate describes chronic food preoccupation consistent with binge eating disorder, reporting that semaglutide (Ozempic) reduced intrusive food-related thoughts and normalized hunger and satiety cues in a way prior surgical interventions did not. GLP-1 receptor agonists act on hypothalamic and mesolimbic reward pathways, which provides a plausible mechanism for the psychological relief she describes, though semaglutide is not formally approved for binge eating disorder and clinical evidence in this population remains at early-stage. She notes she is discontinuing use during pregnancy, which is appropriate given that semaglutide carries a pregnancy contraindication.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Kate describes chronic food preoccupation consistent with binge eating disorder, reporting that semaglutide (Ozempic) reduced intrusive food-related thoughts and normalized hunger and satiety cues in a way prior surgical interventions did not. GLP-1 receptor agonists act on hypothalamic and mesolimbic reward pathways, which provides a plausible mechanism for the psychological relief she describes, though semaglutide is not formally approved for binge eating disorder and clinical evidence in this population remains at early-stage. She notes she is discontinuing use during pregnancy, which is appropriate given that semaglutide carries a pregnancy contraindication.
  • Semaglutide acts on GLP-1 receptors in reward-processing brain regions, giving the 'food noise' reduction effect real biological plausibility, not just anecdote.
  • A 2023 case series (Kan et al., JAMA Network Open) found GLP-1 receptor agonists reduced binge eating frequency, with some patients reporting near-complete remission of compulsive urges.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Semaglutide acts on GLP-1 receptors in reward-processing brain regions, giving the 'food noise' reduction effect real biological plausibility, not just anecdote.
  • A 2023 case series (Kan et al., JAMA Network Open) found GLP-1 receptor agonists reduced binge eating frequency, with some patients reporting near-complete remission of compulsive urges.
  • Semaglutide is not approved for binge eating disorder. Any use in that context is off-label and should involve a clinician familiar with eating disorder treatment.
  • Wilding et al. (2022, Diabetes, Obesity and Metabolism) found patients regained roughly two-thirds of lost weight within one year of stopping semaglutide, and food preoccupation may return with it.
  • Semaglutide is contraindicated in pregnancy. Kate's plan to stop during pregnancy is appropriate, but the video's casual framing around restarting postpartum lacks necessary clinical context.
  • Bariatric surgery history combined with GLP-1 medication use requires medical supervision, as absorption and response profiles can differ in post-surgical patients.
  • If you recognize yourself in Kate's description of food obsession, a structured eating disorder screening is warranted alongside, not instead of, any conversation about medication.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Kate DeAraugo · TikTok creator

187.7K views on this video

I have battled with binge eating and food noise for as long as I can remember. I have tried everything that you can possibly imagine to make it stop and the only thing that has ever removed the const

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Kate DeAraugo, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.